Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/11/1370 |
| _version_ | 1797511454978473984 |
|---|---|
| author | Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller |
| author_facet | Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller |
| author_sort | Oliver Spiller-Boulter |
| collection | DOAJ |
| description | Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>, 25 <i>Ureaplasma urealyticum,</i> and 40 <i>Mycoplasma hominis</i>). All <i>Mycoplasma hominis</i> isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC<sub>50/90</sub> of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while <i>Ureaplasma</i> isolates had MICs of ≤2 mg/L after 24 h (MIC<sub>50/90</sub> of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two <i>U. urealyticum</i> isolates with additional A2058G mutations of 23S rRNA, and one <i>U. parvum</i> isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating <i>Ureaplasma</i> spp. and <i>Mycoplasma hominis</i> infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of <i>Mycoplasma</i> and <i>Ureaplasma</i> urogenital infections is warranted. |
| first_indexed | 2024-03-10T05:45:30Z |
| format | Article |
| id | doaj.art-bc719c3f63ca4dcc8b8fbc8c3bbac62d |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T05:45:30Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-bc719c3f63ca4dcc8b8fbc8c3bbac62d2023-11-22T22:10:38ZengMDPI AGAntibiotics2079-63822021-11-011011137010.3390/antibiotics10111370Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>Oliver Spiller-Boulter0Susanne Paukner1Ian Boostrom2Kirsty Sands3Edward A. R. Portal4Owen B. Spiller5HealthFirst Consulting, Research Division, Blackwood NP12 3RF, UKNabriva Theraputics AG, 1110 Vienna, AustriaDivision of Infection and Immunity, Department of Medical Microbiology, Cardiff University, 6th Floor University Hospital of Wales, Cardiff CF14 4XN, UKDivision of Infection and Immunity, Department of Medical Microbiology, Cardiff University, 6th Floor University Hospital of Wales, Cardiff CF14 4XN, UKDivision of Infection and Immunity, Department of Medical Microbiology, Cardiff University, 6th Floor University Hospital of Wales, Cardiff CF14 4XN, UKDivision of Infection and Immunity, Department of Medical Microbiology, Cardiff University, 6th Floor University Hospital of Wales, Cardiff CF14 4XN, UKLefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>, 25 <i>Ureaplasma urealyticum,</i> and 40 <i>Mycoplasma hominis</i>). All <i>Mycoplasma hominis</i> isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC<sub>50/90</sub> of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while <i>Ureaplasma</i> isolates had MICs of ≤2 mg/L after 24 h (MIC<sub>50/90</sub> of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two <i>U. urealyticum</i> isolates with additional A2058G mutations of 23S rRNA, and one <i>U. parvum</i> isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating <i>Ureaplasma</i> spp. and <i>Mycoplasma hominis</i> infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of <i>Mycoplasma</i> and <i>Ureaplasma</i> urogenital infections is warranted.https://www.mdpi.com/2079-6382/10/11/1370lefamulin<i>Mycoplasma hominis</i><i>Ureaplasma</i> spp.pleuromutilinsusceptibility testing |
| spellingShingle | Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> Antibiotics lefamulin <i>Mycoplasma hominis</i> <i>Ureaplasma</i> spp. pleuromutilin susceptibility testing |
| title | Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> |
| title_full | Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> |
| title_fullStr | Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> |
| title_full_unstemmed | Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> |
| title_short | Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i> |
| title_sort | determination of in vitro antimicrobial susceptibility for lefamulin pleuromutilin for i ureaplasma i spp and i mycoplasma hominis i |
| topic | lefamulin <i>Mycoplasma hominis</i> <i>Ureaplasma</i> spp. pleuromutilin susceptibility testing |
| url | https://www.mdpi.com/2079-6382/10/11/1370 |
| work_keys_str_mv | AT oliverspillerboulter determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT susannepaukner determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT ianboostrom determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT kirstysands determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT edwardarportal determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT owenbspiller determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi |